03_08 ADAURA Trial

1. Background on adjuvant EGFR therapy
2. Discussion of initial and updated results
3. Hazard Ratios and Context
4. When crossover and access limit generalizability


Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.

1.Herbst et al. JCO.  2023;41(10):1830-1840. doi: 10.1200/JCO.22.02186
2.Wu et al. NEJM. 2023;383:1711-1723. doi:10.1056/NEJMoa2027071
3.       Tsuboi et al. NEJM. 2023;389(2):137-147. doi: 10.1056/NEJMoa2304594
4. West and Gyawali. JAMA Oncol. 2021;7(5):677-678. doi:10.1001/jamaoncol.2020.6752
5. Gyawali and West. JCO. 2021;39(3):175-177. doi: 10.1200/JCO.20.01762
6. Prasad. Plenary Session.  “ADAURA OS Results”. Podcast episode published June 8, 2023 
7. Haslan and Prasad. Ann Oncol. 2018; 29(5):1079–1081. doi: 10.1093/annonc/mdy116
8. Tannock et al. JCO.  2023;41(15):2713-2717 doi: 10.1200/JCO.23.00280


 
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology